Patents by Inventor John D. Lambris

John D. Lambris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180118785
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
    Type: Application
    Filed: July 6, 2017
    Publication date: May 3, 2018
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: John D. Lambris
  • Publication number: 20170305971
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 26, 2017
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Madan Katragadda
  • Publication number: 20170247413
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 31, 2017
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Publication number: 20170246269
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Application
    Filed: March 13, 2017
    Publication date: August 31, 2017
    Inventors: Georgios Hajishengallis, John D. Lambris
  • Publication number: 20170202935
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Application
    Filed: January 27, 2017
    Publication date: July 20, 2017
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, George Hajishengallis
  • Publication number: 20170190741
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
    Type: Application
    Filed: October 22, 2014
    Publication date: July 6, 2017
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: John D. LAMBRIS
  • Publication number: 20170173107
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds include a modified compstatin peptide or analog thereof, comprising an added N-terminal component that improves (1) the binding affinity of the peptide to C3, C3b or C3c and/or (2) the plasma stability and/or plasma residence time of the peptide, as compared with an unmodified compstatin peptide under equivalent conditions. Methods of improving the C3 binding of compstatin or compstatin analogs are also disclosed, as well as methods of designing compstatin analogs with improved C3 binding.
    Type: Application
    Filed: March 16, 2015
    Publication date: June 22, 2017
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John D. LAMBRIS, Daniel RICKLIN
  • Patent number: 9630992
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 25, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 9579360
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 28, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, George Hajishengallis
  • Patent number: 9540626
    Abstract: A potent complement regulator is disclosed. The complement regulator comprises a complement regulatory region connected by a flexible linker to a multifunctional binding region that enables binding to C3b activation/inactivation products and/or oxidation end products, as well as to polyanionic surface markers on host cells. An embodiment of the invention utilizes factor H SCRs 1-4 as the complement regulatory region and factor H SCRs 19 and 20 as the multifunctional binding region, linked together by a poly-Gly linker at least 12 residues in length. Pharmaceutical compositions comprising the complement regulator and methods of using the complement regulator are also disclosed.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 10, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Christoph Schmidt, Daniel Ricklin
  • Patent number: 9371365
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: June 21, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu
  • Patent number: 9358266
    Abstract: Methods for the treatment of sepsis with complement inhibitors are disclosed. In particular, C3 inhibitors, such as Compstatin and Compstatin analogs, are administered at various times following the onset of sepsis to alleviate tissue damage and organ failure, which are hallmarks of the second, extravascular stage of sepsis. Combination therapies for comprehensive treatment of sepsis are also disclosed. Pharmaceutical compositions and kits for use in the methods are disclosed as well.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: June 7, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Fletcher B. Taylor, Florea Lupu, Gary Kinasewitz
  • Publication number: 20160096866
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: September 10, 2015
    Publication date: April 7, 2016
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John D. LAMBRIS, Madan Katragadda
  • Publication number: 20160084820
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 24, 2016
    Inventors: Georgios Hajishengallis, John D. Lambris
  • Patent number: 9180160
    Abstract: Methods for treating or ameliorating the damage resulting from intracerebral hemorrhage are disclosed. The methods involve administration of a complement inhibitor to inhibit C3a or C5a formation or activity in the affected tissue. Pharmaceutical compositions suitable for use in the methods of the invention are also provided.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: November 10, 2015
    Assignees: The Trustees of the University of Pennsylvania, The Trustees of Columbia University
    Inventors: John D. Lambris, E. Sander Connolly, Jr.
  • Patent number: 9169307
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: October 27, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Madan Katragadda
  • Publication number: 20150203539
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
    Type: Application
    Filed: February 2, 2015
    Publication date: July 23, 2015
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John D. LAMBRIS, Hongchang QU
  • Publication number: 20150158913
    Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.
    Type: Application
    Filed: October 22, 2014
    Publication date: June 11, 2015
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: John D. LAMBRIS
  • Publication number: 20150158915
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: September 7, 2012
    Publication date: June 11, 2015
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Publication number: 20150110766
    Abstract: A potent complement regulator is disclosed. The complement regulator comprises a complement regulatory region connected by a flexible linker to a multifunctional binding region that enables binding to C3b activation/inactivation products and/or oxidation end products, as well as to polyanionic surface markers on host cells. An embodiment of the invention utilizes factor H SCRs 1-4 as the complement regulatory region and factor H SCRs 19 and 20 as the multi-functional binding region, linked together by a poly-Gly linker at least 12 residues in length. Pharmaceutical compositions comprising the complement regulator and methods of using the complement regulator are also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 23, 2015
    Applicant: UNIVERSITY ULM
    Inventors: John D. Lambris, Christoph Schmidt, Daniel Ricklin